AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10852444
Drug: Antecedent hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antecedent hypoglycemia of 3.9, 3.3, and 2.9 +/‐ 0.1 mmol/L
Trial: 10852444
Drug: Identical day
RxNorm normalized name: MENTHOL 20 g in 100 mL TOPICAL EMULSION [DentiCalm]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical day 1 hypoglycemia of 3.9, 3.3, and 2.9 +/‐ 0.1 mmol/L
Trial: 31303281
Drug: Lusutrombopag (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lusutrombopag (2 mg) in fed state
Trial: 31303281
Drug: Lusutrombopag (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lusutrombopag (0.75 mg) in fasted state
Trial: 27006014
Drug: Ultrasound-guided lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided lateral femoral cutaneous nerve (LFCN) block with 8 ml of ropivacaine, 7.5 mg/ml (Group Ropivacaine)
Trial: 27006014
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 8 ml of saline (Group Placebo)
Trial: 24631129
Drug: ITCA 650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITCA 650 (20, 40, 60 or 80 μg/day)
Trial: 24631129
Drug: ITCA 650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITCA 650 (80 μg/day)
Trial: 12017402
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg once daily at bedtime
Trial: 1978496
Drug: Remoxipride (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride (low dose: 30-90 mg daily)
Trial: 1978496
Drug: Haloperidol (15-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (15-45 mg daily)
Trial: 1978496
Drug: Remoxipride (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride (all doses)
Trial: 580070
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (CVP: cyclophosphamide, vincristine, and prednisone)
Trial: 580070
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (CVP)
Trial: 580070
Drug: Successive single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successive single agent chemotherapy (C-V-P)
Trial: 9231814
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug controls
Trial: 9231814
Drug: Nifedipine in
RxNorm normalized name: nifedipine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine in combination with another drug
Trial: 9231814
Drug: Nifedipine monotherapy
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine monotherapy vs combined therapy
Trial: 8215633
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) 0.14 mg/kg/day
Trial: 26980460
Drug: Bitopertin 5
RxNorm normalized name: Bitopertin
DrugBank: Bitopertin (DB12426)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitopertin 5 mg/day
Trial: 25651610
Drug: 500 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 g/day banana for 12 weeks
Trial: 7851580
Drug: Low-dose estrogen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose estrogen oral contraceptives (OC)
Trial: 1778190
Drug: Intermittent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent therapy with transdermal glyceryl trinitrate
Trial: 1778190
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo transdermal patches
Trial: 6247910
Drug: Prophylactic granulocyte
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic granulocyte transfusions and oral nonabsorbable antibiotics (group 1)
Trial: 6247910
Drug: Oral nonabsorbable
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nonabsorbable antibiotics alone (group 2)
Trial: 19118875
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel therapy for 3 months
Trial: 17006963
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for moderate varicose veins
Trial: 20415638
Drug: rhGH 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH 1.5 mg scqd + ART for 48 weeks (Arm A)
Trial: 20415638
Drug: ART alone
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ART alone for 24 weeks then rhGH 3.0 mg scqd for 24 weeks (Arm B)
Trial: 1330318
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg sumatriptan
Trial: 1335361
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg sumatriptan
Trial: 6367368
Drug: Adrenergic beta‐receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenergic beta‐receptor blockade with oxprenolol
Trial: 30221438
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no dog-assisted therapy)
Trial: 11451599
Drug: Sucralfate Cream
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate Cream
Trial: 3061311
Drug: Bambuterol 0.270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bambuterol 0.270 mg/kg
Trial: 21292895
Drug: Oral miltefosine
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral miltefosine (2.5 mg/kg/day for 28 days)
Trial: 26928838
Drug: Oral Cholera
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Cholera Vaccine (OCV)
Trial: 18415764
Drug: Three disease-modifying
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three disease-modifying anti-rheumatic drugs (DMARDs) and low-dose prednisolone (COMBI)
Trial: 18415764
Drug: Single DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single DMARD with or without low-dose prednisolone (SINGLE)
Trial: 12028323
Drug: Frovatriptan doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frovatriptan doses of 2.5 to 40 mg
Trial: 12028323
Drug: Frovatriptan doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frovatriptan doses of 0.5 mg and 1 mg
Trial: 12028323
Drug: Frovatriptan dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frovatriptan dose of 2.5 mg
Trial: 12028323
Drug: Frovatriptan doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frovatriptan doses above 2.5 mg
Trial: 12028323
Drug: Frovatriptan doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frovatriptan doses of 10 mg and above
Trial: 10726234
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg for 1 week
Trial: 10726234
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg for 3 weeks
Trial: 2220578
Drug: Bepridil (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil (300 to 500 mg/day)
Trial: 2220578
Drug: Diltiazem (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (180 to 300 mg/day)
Trial: 19646174
Drug: Burnout intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Burnout intervention programme (details on dosage and duration not available)
Trial: 17825695
Drug: Placebo (100-mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100-mL saline)
Trial: 17825695
Drug: Intravenous tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tramadol 100 mg in 100-mL saline
Trial: 2406858
Drug: Liquid bismuth
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid bismuth subsalicylate (BSS) 60 mL four times daily (4.2 g of BSS/d) for 3 weeks
Trial: 2406858
Drug: BSS 2
RxNorm normalized name: BSS Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSS 2 tablets four times daily (2.1 g of BSS/d) for 3 weeks
Trial: 2406858
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets taken four times daily) for 3 weeks
Trial: 8032581
Drug: Dipyrone 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 2.5 g
Trial: 31536806
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE 0.625 mg/day) alone
Trial: 28891251
Drug: Baricitinib 4
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4 mg q.d.
Trial: 28891251
Drug: Baricitinib 2
RxNorm normalized name: baricitinib 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 2 mg q.d.
Trial: 28891251
Drug: Baricitinib (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib (twice-daily regimen)
Trial: 26702941
Drug: Standard treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatments (group B)
Trial: 24806137
Drug: Nefopam and
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam and Meperidine (both at 0.1 μg/mL)
Trial: 27997725
Drug: Emollient cream
RxNorm normalized name: EMOLLIENT CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient cream (Dexeryl®) containing glycerol 15%, liquid and soft paraffin 10%, and other ingredients, applied twice daily for 27 ± 2 days
Trial: 27585792
Drug: Cann‐CBD (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cann‐CBD (8 mg THC)
Trial: 27585792
Drug: Cann +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cann + CBD (8 mg THC + 10 mg CBD)
Trial: 27585792
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-dependent, drug-using)
Trial: 25158709
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A injections into the orbicularis oris muscle
Trial: 25158709
Drug: Vehicle injections
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle injections into the orbicularis oris muscle
Trial: 22178274
Drug: Two-needle technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-needle technique for TMJ arthrocentesis plus hyaluronic acid injections
Trial: 16635050
Drug: Active analgesics
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active analgesics
Trial: 15579788
Drug: Low-dose T3
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose T3 (25 microg) with paroxetine 30 mg daily
Trial: 15579788
Drug: High-dose T3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose T3 (25 microg twice daily) with paroxetine 30 mg daily
Trial: 15579788
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with paroxetine 30 mg daily
Trial: 12959313
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg day(‐1))
Trial: 2825462
Drug: atracurium 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atracurium 0.02 mg/kg
Trial: 2825462
Drug: atracurium 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atracurium 0.03 mg/kg
Trial: 2825462
Drug: atracurium 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atracurium 0.04 mg/kg
Trial: 9424681
Drug: atracurium 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atracurium 0.05 mg/kg
Trial: 18447946
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with a proton pump inhibitor
Trial: 7847434
Drug: TMP/SMX thrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP/SMX thrice weekly (3 times per week)
Trial: 7847434
Drug: TMP/SMX daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP/SMX daily (twice daily)
Trial: 1826822
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of abrasio and high-dose gestagen treatment
Trial: 31171928
Drug: Domperidone treatment
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone treatment for 14 days
Trial: 24163093
Drug: Continuous intraarticular
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intraarticular infusion of 0.2% ropivacaine
Trial: 23136289
Drug: Community managed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community managed cases (excluding cost of antibiotics)
Trial: 23136289
Drug: Referred cases
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referred cases (excluding cost of antibiotics)
Trial: 11175678
Drug: Timed 'Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timed 'Up & Go' test (TUG) during 'on' phase of levodopa (1 hour after administration)
Trial: 2878457
Drug: 0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g/kg ethanol (control)
Trial: 7949539
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron supplementation (FeDs, n = 12)
Trial: 3357722
Drug: Diet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet therapy and behavior change
Trial: 21873922
Drug: Office-based vergence/accommodative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office-based vergence/accommodative therapy with home reinforcement (OBVAT)
Trial: 19668097
Drug: Home-based computer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based computer vergence/accommodative therapy and pencil push-ups (HBCVAT+)
Trial: 18852411
Drug: Office-based placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office-based placebo therapy with home reinforcement (OBPT)
Trial: 18284711
Drug: CoQ10 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 (300 mg per day for 20 days)
Trial: 18284711
Drug: Placebo (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (300 mg per day for 20 days)
Trial: 12220476
Drug: Urinary LTE4
RxNorm normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary LTE4 excretion
Trial: 10574416
Drug: Benidipine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benidipine treatment
Trial: 1767175
Drug: Troxerutine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troxerutine (4 g/day)
Trial: 6123277
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine orally at 2200 hours on the evening before surgery and a further 150 mg 1-2 hours before operation (Group A)
Trial: 6123277
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine with premedication only (Group B)
Trial: 19329822
Drug: rosuvastatin, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin, 20 mg per day
Trial: 14704596
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (niacin, bile acid sequestrant, ezetimibe)
Trial: 9825271
Drug: Ibuprofen-arginine (IA)
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen-arginine (IA) 400 mg
Trial: 3081148
Drug: Conventional combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional combined test using insulin together with thyrotrophin releasing hormone and luteinising hormone releasing hormone
Trial: 18955431
Drug: Weekly phone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly phone call (control group)
Trial: 11264333
Drug: Medication plus
RxNorm normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication plus 16 sessions of manualized group psychotherapy
Trial: 11264333
Drug: Continued medication
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued medication only (fluoxetine)
Trial: 9497790
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin infusion (28.9 +/- 2.1 mu-units/ml)
Trial: 9497790
Drug: High-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose insulin infusion (101.7 +/- 6.8 mu-units/ml)
Trial: 3092712
Drug: Auranofin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auranofin (6 mg/d)
Trial: 3092712
Drug: D-penicillamine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penicillamine (250 mg/d for 4 weeks, 500 mg/d for 4 weeks, then 750 mg/d thereafter)
Trial: 12126343
Drug: Standard pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmacotherapy alone
Trial: 27404027
Drug: Ospemifene 60
RxNorm normalized name: ospemifene 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ospemifene 60 mg/d
Trial: 24178236
Drug: Mirabegron OCAS
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron OCAS 25-400 mg single doses
Trial: 24178236
Drug: Mirabegron OCAS
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron OCAS up to 400 mg single doses
Trial: 24178236
Drug: Mirabegron OCAS
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron OCAS up to 200 mg multiple doses
Trial: 17618766
Drug: Posterior colporrhaphy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior colporrhaphy, site-specific repair, site-specific repair with Fortagen graft augmentation (specific intervention details not provided)
Trial: 11805614
Drug: Sygen (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sygen (two doses)
Trial: 9543170
Drug: Hydrocortisone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (25 mg as an i.v. bolus)
Trial: 17056948
Drug: ondansetron, droperidol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron, droperidol, or their combination
Trial: 7028532
Drug: Maprotiline (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline (reference drug)
Trial: 26049702
Drug: Molecular imaging
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular imaging as a biomarker for targeted cancer therapy
Trial: 9271481
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (up to 1.25 mg of conjugated equine estrogens daily, along with 5 mg of medroxyprogesterone acetate daily)
Trial: 9241623
Drug: Simvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10 mg daily)
Trial: 8511810
Drug: Chloroquine-Proguanil combination
RxNorm normalized name: chloroquine / proguanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine-Proguanil combination (CQ+PROG)
Trial: 20692561
Drug: Besifloxacin 0.6%
RxNorm normalized name: BESIFLOXACIN 0.6% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Besifloxacin 0.6% ophthalmic suspension
Trial: 8450081
Drug: Metronidazole 200
RxNorm normalized name: metronidazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 200 mg x 3 x 10 days
Trial: 8450081
Drug: Tetracycline 250
RxNorm normalized name: tetracycline 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline 250 mg x 4 x 12 days
Trial: 3096763
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate 100 mg daily for four weeks
Trial: 2974306
Drug: Acitretin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin (10 mg capsules, 3 capsules/day for 4 weeks, followed by varying doses for 8 weeks)
Trial: 2974306
Drug: Etretinate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etretinate (10 mg capsules, 3 capsules/day for 4 weeks, followed by varying doses for 8 weeks)
Trial: 28941589
Drug: Dexamethasone (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (12 mg intravenous before chemoembolization)
Trial: 20037525
Drug: Rectal suppository
RxNorm normalized name: Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal suppository (50 mg)
Trial: 20037525
Drug: Tablet (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet (50 mg)
Trial: 16390864
Drug: GH +
RxNorm normalized name: Delsym Cough + Cold Daytime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH + sex steroids